Lanean...
Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
The recent introduction of direct-acting antiviral drugs (DAAs) for treatment of the hepatitis C virus (HCV) has greatly improved the management of HCV for infected patients. These viral protein inhibitors act rapidly, allowing HCV clearance and increasing the sustained virological response rates. H...
Gorde:
| Argitaratua izan da: | World J Gastroenterol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Baishideng Publishing Group Inc
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5487495/ https://ncbi.nlm.nih.gov/pubmed/28706414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v23.i24.4317 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|